Capricor Therapeutics (CAPR) Competitors $6.69 -0.01 (-0.15%) Closing price 04:00 PM EasternExtended Trading$6.72 +0.02 (+0.37%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CAPR vs. SNDX, SION, XERS, TSHA, ZYME, NUVB, ARDX, AMPH, TRML, and PHVSShould you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Syndax Pharmaceuticals (SNDX), Sionna Therapeutics (SION), Xeris Biopharma (XERS), Taysha Gene Therapies (TSHA), Zymeworks (ZYME), Nuvation Bio (NUVB), Ardelyx (ARDX), Amphastar Pharmaceuticals (AMPH), Tourmaline Bio (TRML), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry. Capricor Therapeutics vs. Its Competitors Syndax Pharmaceuticals Sionna Therapeutics Xeris Biopharma Taysha Gene Therapies Zymeworks Nuvation Bio Ardelyx Amphastar Pharmaceuticals Tourmaline Bio Pharvaris Capricor Therapeutics (NASDAQ:CAPR) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment. Does the media refer more to CAPR or SNDX? In the previous week, Capricor Therapeutics and Capricor Therapeutics both had 4 articles in the media. Syndax Pharmaceuticals' average media sentiment score of 0.77 beat Capricor Therapeutics' score of 0.25 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Syndax Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate CAPR or SNDX? Capricor Therapeutics presently has a consensus price target of $22.25, indicating a potential upside of 232.59%. Syndax Pharmaceuticals has a consensus price target of $39.22, indicating a potential upside of 160.79%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Capricor Therapeutics is more favorable than Syndax Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capricor Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89Syndax Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82 Which has higher earnings and valuation, CAPR or SNDX? Capricor Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapricor Therapeutics$22.27M13.73-$40.47M-$1.64-4.08Syndax Pharmaceuticals$77.93M16.62-$318.76M-$3.89-3.87 Do institutionals and insiders have more ownership in CAPR or SNDX? 21.7% of Capricor Therapeutics shares are owned by institutional investors. 10.5% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is CAPR or SNDX more profitable? Capricor Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -428.48%. Capricor Therapeutics' return on equity of -62.71% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Capricor TherapeuticsN/A -62.71% -50.82% Syndax Pharmaceuticals -428.48%-130.47%-56.12% Which has more volatility & risk, CAPR or SNDX? Capricor Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. SummaryCapricor Therapeutics beats Syndax Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPR vs. The Competition Export to ExcelMetricCapricor TherapeuticsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$306.30M$10.68B$6.11B$10.47BDividend YieldN/A1.91%5.73%4.77%P/E Ratio-4.0820.5185.3627.36Price / Sales13.7326.68607.44135.43Price / CashN/A25.0737.4661.86Price / Book2.093.4812.426.81Net Income-$40.47M$208.83M$3.32B$276.80M7 Day Performance-10.56%-0.29%1.01%0.27%1 Month Performance10.76%3.71%10.75%8.31%1 Year Performance-69.03%-4.01%76.20%35.60% Capricor Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPRCapricor Therapeutics1.9312 of 5 stars$6.69-0.1%$22.25+232.6%-65.8%$306.30M$22.27M-4.08101SNDXSyndax Pharmaceuticals3.645 of 5 stars$16.40+5.1%$39.22+139.2%-22.8%$1.34B$23.68M-4.22110SIONSionna Therapeutics2.5261 of 5 stars$29.25-2.5%$38.00+29.9%N/A$1.32BN/A0.0035News CoverageInsider TradeXERSXeris Biopharma2.9943 of 5 stars$8.13-0.9%$7.08-12.9%+173.4%$1.32B$203.07M-38.71290News CoverageAnalyst UpgradeTSHATaysha Gene Therapies2.4005 of 5 stars$4.42-7.1%$9.00+103.6%+159.3%$1.30B$8.33M-13.00180Gap UpZYMEZymeworks0.066 of 5 stars$16.68-1.5%N/AN/A$1.27B$76.30M-17.20460News CoverageAnalyst UpgradeNUVBNuvation Bio2.8057 of 5 stars$3.77+1.6%$7.86+108.4%+54.9%$1.27B$7.87M-5.9860Analyst ForecastARDXArdelyx4.3454 of 5 stars$5.20-1.1%$11.70+125.0%-16.4%$1.27B$333.61M-22.6190News CoverageAnalyst RevisionAMPHAmphastar Pharmaceuticals4.5656 of 5 stars$26.58-0.6%$31.60+18.9%-51.6%$1.24B$722.68M9.962,028News CoverageTRMLTourmaline Bio1.5155 of 5 stars$47.87-0.1%$45.65-4.6%+87.6%$1.23BN/A-13.9644PHVSPharvaris2.7459 of 5 stars$23.25-0.6%$34.00+46.2%+1.9%$1.22BN/A-6.9230News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies SNDX Competitors SION Competitors XERS Competitors TSHA Competitors ZYME Competitors NUVB Competitors ARDX Competitors AMPH Competitors TRML Competitors PHVS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CAPR) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
